Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Anixa Biosciences Inc (DE:A2N6ZF)
STUTTGART:A2N6ZF
Holding DE:A2N6ZF?
Track your performance easily
A2N6ZF Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€2.20 - €4.66
Previous Close€2.32
Volume0.00
Average Volume (3M)250.00
Market Cap
€71.40M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.61
Next Earnings
Mar 08, 2024EPS Estimate
-€0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. Volume250
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€11.05Price Target Upside376.43% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Anixa Biosciences News
PremiumCompany Announcements
Anixa Biosciences Forms Cancer Vaccine Partnership with Cleveland Clinic
PremiumCompany Announcements
Anixa Biosciences Stockholders Affirm Confidence and Oversight
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
4.53% Other Institutional Investors
95.47% Public Companies and
Individual Investors
A2N6ZF FAQ
What was Anixa Biosciences Inc’s price range in the past 12 months?
Anixa Biosciences Inc lowest stock price was €2.20 and its highest was €4.66 in the past 12 months.
What is Anixa Biosciences Inc’s market cap?
Currently, no data Available
When is Anixa Biosciences Inc’s upcoming earnings report date?
Anixa Biosciences Inc’s upcoming earnings report date is Mar 08, 2024 which is 289 days ago.
How were Anixa Biosciences Inc’s earnings last quarter?
Anixa Biosciences Inc released its earnings results on Mar 10, 2023. The company reported -€0.074 earnings per share for the quarter, beating the consensus estimate of -€0.147 by €0.074.
Is Anixa Biosciences Inc overvalued?
According to Wall Street analysts Anixa Biosciences Inc’s price is currently Undervalued.
Does Anixa Biosciences Inc pay dividends?
Anixa Biosciences Inc does not currently pay dividends.
What is Anixa Biosciences Inc’s EPS estimate?
Anixa Biosciences Inc’s EPS estimate is -€0.08.
How many shares outstanding does Anixa Biosciences Inc have?
Currently, no data Available
What happened to Anixa Biosciences Inc’s price movement after its last earnings report?
Anixa Biosciences Inc reported an EPS of -€0.074 in its last earnings report, beating expectations of -€0.147. Following the earnings report the stock price went down -1.266%.
Which hedge fund is a major shareholder of Anixa Biosciences Inc?
Currently, no hedge funds are holding shares in DE:A2N6ZF
---
Anixa Biosciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€11.05 (376.43% Upside)
€11.05 (376.43% Upside)
Blogger Sentiment
Bullish
DE:A2N6ZF Sentiment 100%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth $182.1K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-20.58%
12-Months-Change
Fundamentals
Return on Equity
-41.01%
Trailing 12-Months
Asset Growth
-10.37%
Trailing 12-Months
Company Description
Anixa Biosciences Inc
Anixa Biosciences, Inc. is a cancer-focused biotechnology company, which focuses on harnessing the body's immune system in the fight against cancer. It operates through the following segments: Cancer Diagnostics, Cancer Therapeutics, and Legacy Patent Licensing Activities. Cancer Diagnostic segment develops CchekTM platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the body's immune response to the presence of a malignancy. Cancer Therapeutics segment offers chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient's own immune cells to fight cancer. The company was founded on November 5, 1982 and is headquartered San Jose, CA.
---
A2N6ZF Stock 12 Month Forecast
Average Price Target
€11.05
▲(376.43% Upside)
Technical Analysis
Anixa Biosciences
―
Annovis Bio
―
Aptevo Therapeutics
―
Aptose Biosciences
―
Arrowhead Pharmaceuticals
―
Best Analysts Covering A2N6ZF
1 Year
1 Year Success Rate
3/20 ratings generated profit
1 Year Average Return
-17.11%
reiterated a buy rating 9 months ago
Copying Yi Chen's trades and holding each position for 1 Year would result in 15.00% of your transactions generating a profit, with an average return of -17.11% per trade.
---